胃癌在世界范围内发病率高，死亡率也高，近些年肠型胃癌发病率有所下降，但弥漫型胃癌发病率不降反升。已知上皮型钙黏蛋白（E-cadherin, E-cd）与肿瘤的发生、侵袭和转移有关。E-cd胚系突变是遗传性弥漫型胃癌发病的遗传学基础，散发性弥漫型胃癌中常见其表达下调，但其下调的临床病理意义尤其是预后意义仍无定论。本文对E-cd在散发性弥漫型胃癌的表达情况及其下调机制进行了综述。

Gastric carcinoma(GC) is highly prevalent worldwide with a high rate of death. Although the incidence of intestinal GC has declined gradually, the incidence of diffuse GC has remained stable or even increased. It was well established that E-cadherin(E-cd) loss is involved in tumor initiation, infiltration and metastasis. E-cd germ line mutation is the genetic foundation for the hereditary diffuse GC. The down-regulation of E-cd expression was also observed in sporadic diffuse GC, yet its clinicopathologic significance, particularly to the prognosis of GC remains largely unknown. In this article, we reviewed expression pattern of E-cd in sporadic GC and its significance. The molecular mechanisms responsible for E-cd down-regulation in sporadic diffuse GC were also discussed.

［1］Crew KD, Neugut AI. Epidemiology of gastric cancer［J］. World J Gastroenterol, 2006,12(3):354-362.
［2］Henson DE, Dittus C, Younes M, et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type［J］. Arch Pathol Lab Med, 2004,128(7):765-770.
［3］Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System［M］. Lyon: IARC Press,2000:42-45.
［4］Ekstrom AM, Serafini M, Nyren O, et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden［J］. Int J Cancer, 2000,87(1):133-140.
［5］Chan AO. E-cadherin in gastric cancer［J］. World J Gastroenterol, 2006,12(2):199-203.
［6］Yoon CS, Hyung WJ, Lee JH, et al. Expression of S100A4, E-cadherin, alpha- and beta-catenin in gastric adenocarcinoma［J］. Hepatogastroenterology, 2008,55(86-87):1916-1920.
［7］Arévalo F, Monge E, Morales D. E-cadherin molecular expresion in the diffuse and intestinal types of gastric adenocarcinoma. A report from Lima, Peru［J］. Rev Esp Enferm Dig, 2007,99(6):325-329.
［8］Walch A, Seidl S, Hermannstdter C, et al. Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer［J］. Mod Pathol, 2008,21(5):544-552.
［9］Guzmán P, Araya J, Villaseca M, et al. Immunohistochemical expression of the E-cadherin-catenin complex in gastric cancer［J］. Rev Med Chil, 2006,134(8):1002-1009.
［10］Lee KH, Shin SJ, Kim KO, et al. Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma［J］. Oncol Rep, 2006,16(4):823-830.
［11］Zhong XY, Zhang LH, Jia SQ, et al. Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer［J］. Histopathology, 2008,52(5):560-568.
［12］Kim JH, Park JM, Jung CW, et al. The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma［J］. J Surg Oncol, 2008,97(2):125-130.
［13］Kim DY, Joo JK, Park YK, et al. E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis［J］. J Surg Oncol, 2007,96(5):429-435.
［14］Aoki R, Yasuda M, Torisu R, et al. Relationship between lymph node metastasis and E-cadherin expression in submucosal invasive gastric carcinomas with gastric-phenotype［J］. J Med Invest, 2007,54(1-2):159-167.
［15］Boo YJ, Park SS, Kim JH, et al. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers［J］. J Surg Oncol, 2007,95(2):110-117.
［16］Theuer CP, Al-Kuran R, Akiyama Y, et al. Increased epithelial cadherin expression among Japanese intestinal-type gastric cancers compared with specimens from American patients of European descent［J］. Am Surg, 2006,72(4):332-338.
［17］Berx G, Becker KF, Hofler H, et al. Mutations of the human E-cadherin (CDH1) gene［J］. Hum Mutat, 1998,12(4):226-237.
［18］Costello JF, Plass C. Methylation matters［J］. J Med Genet, 2001, 38(5):285-303.
［19］Wang L, Zhang F, Wu PP, et al. Disordered beta-catenin expression and E-cadherin/CDH1 promoter methylation in gastric carcinoma［J］. World J Gastroenterol, 2006,12(26):4228-4231.
［20］Zazula M, Ferreira AM, Czopek JP, et al. CDH1 gene promoter hypermethylation in gastric cancer: relationship to Goseki grading, microsatellite instability status, and EBV invasion［J］. Diagn Mol Pathol, 2006,15(1):24-29.
［21］Ikoma H, Ichikawa D, Koike H, et al. Correlation between serum DNA methylation and prognosis in gastric cancer patients［J］. Anticancer Res, 2006,26(3B):2313-2316.
［22］Liu YC, Shen CY, Wu HS, et al. Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas［J］. World J Gastroenterol, 2006,12(14):2168-2173.
［23］Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2［J］. J Biol Chem, 2008,283(22):14910-14914.
［24］Nakada C, Matsuura K, Tsukamoto Y, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c［J］. J Pathol, 2008,216(4):418-427.
［25］Gandellini P, Folini M, Longoni N, et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon［J］. Cancer Res, 2009,69(6):2287-2295.
［26］Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2［J］. Genes Dev, 2008,22(7):894-907.
［27］Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1［J］. Nat Cell Biol, 2008,10(5):593-601.
［28］Nakada C, Matsuura K, Tsukamoto Y, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c［J］. J Pathol, 2008,216(4):418-427.
［29］Hurteau GJ, Carlson JA, Spivack SD, et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin［J］. Cancer Res, 2007,67(17):7972-7976.
［30］Hurteau GJ, Carlson JA, Roos E, et al. Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression［J］. Cell Cycle, 2009, 8(13): 2064-2069.
［31］Place RF, Li LC, Pookot D, et al. MicroRNA-373 induces expression of genes with complementary promoter sequences［J］. Proc Natl Acad Sci USA, 2008,105(5):1608-1613.